SEC Comment Letter 0000000000-23-003546 to Arcadia Biosciences, Inc. (RKDA) (CIK 0001469443) (RKDA)

Arcadia Biosciences, Inc. (RKDA) (CIK 0001469443)
Date: April 10, 2023 · CIK: 0001469443 · Accession: 0000000000-23-003546

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-271082

Date

April 10, 2023

Author

Not clearly detected

Form

UPLOAD

Company

Arcadia Biosciences, Inc. (RKDA) (CIK 0001469443)

Letter

United States securities and exchange commission logo April 10, 2023 Stanley E. Jacot, Jr. President and Chief Executive Officer Arcadia Biosciences, Inc. 5950 Sherry Lane, Suite 215 Dallas, TX 75225 Re:Arcadia Biosciences, Inc. Registration Statement on Form S-3 Filed April 3, 2023 File No. 333-271082 Dear Stanley E. Jacot: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Conlon Danberg at 202-551-4466 with any questions. Sincerely, Division of Corporation Finance Office of Industrial Applications and Services cc: Jeffrey Pietsch, Esq.

Show Raw Text

United States securities and exchange commission logo
April 10, 2023
Stanley E. Jacot, Jr.
President and Chief Executive Officer
Arcadia Biosciences, Inc.
5950 Sherry Lane, Suite 215
Dallas, TX 75225
Re:Arcadia Biosciences, Inc.
Registration Statement on Form S-3
Filed April 3, 2023
File No. 333-271082
Dear Stanley E. Jacot:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Conlon Danberg at 202-551-4466 with any questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services
cc:       Jeffrey Pietsch, Esq.

SecProbe.io